Business
Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold
Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative
About this update from Sensus Healthcare, Inc.
[{"type":"text","content":"Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarterLaunched the “Fair Deal Agreement” recurring revenue program to provide an equipment placement option and complement the fair market value lease program for SRT systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three months ended March 31, 2024. Highlights from the first quarter of 2024 and recent weeks include the following (all comparisons are with the first quarter of 2023, unless otherwise noted): Revenues were $10.7 million, compared with $3.4 million, an increase of 214%, reflecting higher superficial radiotherapy (SRT and IG-SRT) unit salesShipped 26 systems, compared with 10 systemsNet income was $2.3 million, or $0.14 per diluted share, compared with a net loss of $1.9 million, or $0.12 per shareEnded the quarter with $14.7 million in cash and cash equivalents, and no debtAccounts receivable as of March 31, 2024 were $19.6 million, compared with $10.6 million as of December 31, 2023Continued to build inventories to prepare for anticipated customer demandLaunched “Fair Deal Agreement” recurring revenue program for the SRT-100 Vision™ (IG-SRT)Showcased all products and services at the Winter Clinical and South Beach Symposium, and at the American Academy of Dermatology Annual MeetingEngaged CureRays to provide oversight and supervision for customers involved with the recurring revenue program and to enhance patient safety; CureRays will also conduct clinical studies to expand indications for SRT, beginning with inflammatory diseasesIssued a U.S. patent for SRT-100 Vision System (IG-SRT) treatment planning capabilitiesSold first SRT-100 Vision System (IG-SRT) in Asia, to Far Eastern Memorial Hospital in TaiwanMade first commercial sale of an SRT-100 for veterinary use outside the U.S., to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge Farm at Beit Verl College in Tel Aviv, to provide a gentler radiotherapy o...